Seres Free Cash Flow vs Change In Cash Analysis
MCRB Stock | USD 0.88 0.02 2.33% |
Seres Therapeutics financial indicator trend analysis is much more than just breaking down Seres Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Seres Therapeutics is a good investment. Please check the relationship between Seres Therapeutics Free Cash Flow and its Change In Cash accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.
Free Cash Flow vs Change In Cash
Free Cash Flow vs Change In Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Seres Therapeutics Free Cash Flow account and Change In Cash. At this time, the significance of the direction appears to have weak relationship.
The correlation between Seres Therapeutics' Free Cash Flow and Change In Cash is 0.32. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Change In Cash in the same time period over historical financial statements of Seres Therapeutics, assuming nothing else is changed. The correlation between historical values of Seres Therapeutics' Free Cash Flow and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Seres Therapeutics are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Free Cash Flow i.e., Seres Therapeutics' Free Cash Flow and Change In Cash go up and down completely randomly.
Correlation Coefficient | 0.32 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Change In Cash
Most indicators from Seres Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Seres Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.The current year's Selling General Administrative is expected to grow to about 92.1 M, whereas Issuance Of Capital Stock is forecasted to decline to about 12.3 M.
2023 | 2024 (projected) | Non Recurring | 1.3M | 1.2M | Reconciled Depreciation | 6.2M | 5.5M |
Seres Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Seres Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Seres Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 132.4M | 342.9M | 354.9M | 348.8M | 358.6M | 225.8M | |
Other Current Liab | 10.9M | 21.7M | 38.5M | 105.0M | 73.9M | 77.6M | |
Total Current Liabilities | 46.0M | 46.4M | 82.3M | 85.6M | 98.7M | 103.6M | |
Total Stockholder Equity | (48.3M) | 174.8M | 131.5M | 10.8M | (44.9M) | (42.6M) | |
Property Plant And Equipment Net | 30.9M | 22.9M | 36.1M | 134.0M | 132.3M | 138.9M | |
Net Debt | (20.3M) | (75.3M) | (130.8M) | (440K) | 86.0M | 90.3M | |
Retained Earnings | (459.6M) | (548.8M) | (614.4M) | (864.5M) | (978.2M) | (929.3M) | |
Accounts Payable | 4.9M | 4.0M | 13.7M | 17.4M | 3.6M | 6.7M | |
Cash | 65.1M | 116.0M | 180.0M | 163.0M | 128.0M | 93.9M | |
Non Current Assets Total | 32.3M | 74.2M | 51.2M | 154.0M | 183.2M | 192.3M | |
Cash And Short Term Investments | 94.8M | 253.6M | 290.7M | 181.3M | 128.0M | 156.3M | |
Common Stock Shares Outstanding | 56.6M | 79.8M | 91.7M | 108.1M | 128.0M | 134.4M | |
Other Current Assets | 33.3M | 11.5M | 25.8M | 13.4M | 9.1M | 10.4M | |
Total Liab | 180.8M | 168.2M | 223.4M | 338.0M | 403.5M | 423.6M | |
Total Current Assets | 100.2M | 268.8M | 303.6M | 194.8M | 175.4M | 166.7M | |
Common Stock | 70K | 91K | 92K | 125K | 135K | 141.8K | |
Short Long Term Debt Total | 44.8M | 40.8M | 49.2M | 162.6M | 213.9M | 224.6M | |
Other Liab | 94.4M | 86.6M | 98.5M | 93.9M | 108.0M | 78.0M | |
Current Deferred Revenue | 25.8M | 22.6M | 16.8M | 4.3M | 7.7M | 13.6M | |
Common Stock Total Equity | 70K | 91K | 92K | 125K | 143.8K | 150.9K | |
Liabilities And Stockholders Equity | 132.4M | 342.9M | 354.9M | 348.8M | 358.6M | 245.7M | |
Non Current Liabilities Total | 134.8M | 121.8M | 141.1M | 252.4M | 304.8M | 320.0M | |
Other Stockholder Equity | 411.3M | 723.5M | 745.8M | 875.2M | 933.2M | 979.9M | |
Property Plant And Equipment Gross | 30.9M | 22.9M | 36.1M | 134.0M | 183.4M | 192.6M | |
Accumulated Other Comprehensive Income | (27.7M) | (47K) | (60K) | (12K) | (13.8K) | (14.5K) | |
Short Term Debt | 4.5M | 5.6M | 13.2M | 4.1M | 13.4M | 7.8M | |
Property Plant Equipment | 19.5M | 13.9M | 36.1M | 23.0M | 26.4M | 21.7M | |
Net Tangible Assets | (48.3M) | 174.8M | 131.5M | 10.8M | 9.7M | 9.2M | |
Short Term Investments | 113.9M | 0.0 | 29.7M | 137.6M | 110.7M | 18.3M | |
Retained Earnings Total Equity | (459.6M) | (548.8M) | (614.4M) | (864.5M) | (778.1M) | (739.2M) | |
Capital Surpluse | 411.3M | 723.5M | 745.8M | 875.2M | 1.0B | 552.2M | |
Non Current Liabilities Other | 110.1M | 97.1M | 116.5M | 201.8M | 1.6M | 1.5M | |
Capital Lease Obligations | 20.1M | 15.7M | 24.6M | 111.5M | 112.4M | 118.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.871 | Quarterly Revenue Growth (0.93) | Return On Assets (0.1) | Return On Equity (15.56) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.